- Aptevo Therapeutics (APVO, Financial) announces innovative APVO711 in preclinical development, targeting resistant solid tumors.
- APVO711 employs a dual mechanism, enhancing T-cell activation and PD-L1 inhibition for deeper immune responses.
- The proprietary ADAPTIR® platform underpins APVO711's potential, showcasing Aptevo's pipeline versatility.
Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company, has provided a significant update on APVO711, their preclinical-stage bispecific therapeutic candidate. APVO711 is designed to enhance cancer treatment efficacy by combining PD-L1 checkpoint inhibition with CD40 immune activation. This dual mechanism approach aims to provide a potent and sustained response, especially for solid tumors resistant to conventional therapies.
Currently in the preclinical phase, APVO711 promises broad applications across various solid tumor types. The therapy leverages Aptevo's proprietary ADAPTIR® platform technology, which allows the bispecific candidate to block tumor-driven immune suppression while simultaneously engaging T-cells for robust anti-tumor activity. This innovative approach sets APVO711 apart from traditional immunotherapies by addressing both immune activation and suppression in one treatment.
The company's lead candidate, mipletamig, continues to demonstrate strong efficacy and safety in acute myeloid leukemia (AML) trials, further validating Aptevo's strategic focus on developing novel bispecific immunotherapies. With the ADAPTIR® platform's demonstrated capacity for engineering complex therapeutic candidates, Aptevo is poised to advance treatments for cancers with significant unmet needs.
"APVO711 represents a breakthrough in immunotherapy, targeting both PD-L1 and CD40 to enhance the immune system’s fight against cancer," said Marvin White, President and CEO of Aptevo Therapeutics. "Our goal is to expand the benefits of immunotherapy to more patients, particularly those for whom standard checkpoint inhibitors have failed."
